ArticleJournal of neuro-oncology2020
Extracellular glutamate and IDH1
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- 7T GluCEST in Discriminating Gliomas with Diverse Invasiveness Degrees and Its Association with Invasion Indices.ACS chemical neuroscience · 2025Article
- Review
- Evolutionary Changes in Primate Glutamate Dehydrogenases 1 and 2 Influence the Protein Regulation by Ligands, Targeting and Posttranslational Modifications.International journal of molecular sciences · 2024Review
- Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.International journal of molecular sciences · 2022Article
- Impact ofBiomedicines · 2022Article
- Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Cell reports. Medicine · 2021Review
- The implications of IDH mutations for cancer development and therapy.Nature reviews. Clinical oncology · 2021Review
- D-2-Hydroxyglutarate in Glioma Biology.Cells · 2021Review
- Central nervous system tumors and three-dimensional cell biology: Current and future perspectives in modeling.World journal of stem cells · 2021Review
- Association ofCells · 2021Article
- The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma.Translational oncology · 2020Article
- Pathways of 4-Hydroxy-2-Nonenal Detoxification in a Human Astrocytoma Cell Line.Antioxidants (Basel, Switzerland) · 2020Article
- Editorial: advances in neuro-oncology and clinical treatment-from ASNO 2019.Journal of neuro-oncology · 2020Article
- Metabolic plasticity of IDH1Cancer & metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposeSomatic mutations of the isocitrate dehydrogenase 1 (IDH1) gene, mostly substituting Arg132 with histidine, are associated with better patient survival, but glioma recurrence and progression are nearly inevitable, resulting in disproportionate morbidity and mortality. Our previous studies demonstrated that in contrast to hemizygous IDH1
methodsRNA sequencing data of IDH1
resultsIn contrast to IDH1
conclusion3D culture is more relevant to IDH1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.